Company
Headquarters: Miaoli, Taiwan
Employees: 257
TW$11.77 Billion
TWD as of July 1, 2024
US$361.5 Million
Company | Market Cap (USD) |
---|---|
Novo Nordisk | $622.07 B |
Vertex Pharmaceuticals Incorporated | $121.36 B |
Regeneron Pharmaceuticals, Inc. | $115.11 B |
CSL Limited | $95.75 B |
Marinomed Biotech AG | $75.67 B |
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
Mycenax Biotech Inc. develops and manufactures biopharmaceutical products from mammalian and microbial cell lines in Taiwan, Europe, and the United States. The company develops monoclonal antibodies, bi-specific antibodies, fc-fusion proteins, recombinant proteins, peptides, protein conjugates (non-toxin), antibody-cell conjugates, enzymes, antigen-binding fragments (Fab), and single-chain variable fragments (ScFv), as well as plasmids and DNA vaccines. It also provides process development solutions, including development of production cell lines, upstream and downstream process development, process scale-up, formulation development, and analytical methods; in-house analytical services; GMP manufacturing services, such as drug substance and products manufacturing, and cell banking; and manufacturing technologies. The company was founded in 2001 and is headquartered in Zhubei City, Taiwan.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Mycenax Biotech, Inc. has the following listings and related stock indices.
Stock: TWSE: 4726 wb_incandescent